Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
9.1.2020 15:00:00 EET | Business Wire | Press release
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.
“The impressive preclinical studies at Enleofen have revealed the potential of IL-11 blockade to treat a broad range of diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We are excited to have these monoclonal antibodies in our pipeline and have the opportunity to accelerate their path to many patients whose needs are not met by current treatments.”
IL-11 is a cytokine, a protein certain cells of the body use to communicate, and plays a key role in fibro-inflammatory conditions. Blocking IL-11 action has been shown to inhibit disease across many organs (liver, lung, kidney, retina, bowel, heart and skin). In preclinical studies, antibody-based IL-11 antagonists were able to prevent and reverse inflammation and fibrosis, and restore organ function.
Enleofen is a spin out company from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School under the SingHealth Duke-NUS Academic Medical Centre (AMC), Singapore and exclusively licensed a suite of patents and number of antibody products when it was founded in 2017, from the AMC. Subsequent to this, Enleofen has built an extensive anti-IL-11 antibody platform and advanced its drug development programs towards the clinic. Boehringer Ingelheim will now develop this platform further and plans to work jointly with scientists at the AMC to accelerate the platform into clinical development. The initial focus will be on novel therapies for patients with NASH and ILDs, two of Boehringer Ingelheim’s core disease focus areas, with a potential to expand into further fibro-inflammatory conditions based on IL-11’s central role in disease.
“Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical needs of patients worldwide,” said Prof Stuart Cook, Director and co-founder of Enleofen. “The preclinical data across a range of conditions are unprecedented and this new approach of targeting IL-11 could be a game changer”.
The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Under the terms of the agreement, Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.
For references and notes to editors, please visit:
http://www.boehringer-ingelheim.com/press-release/fibrotic-diseases-partnership-enleofen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005346/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Enleofen
Charu Srivastava
charu@redhill.asia
+65 91810614
Mariyam Haider
mariyam@redhill.asia
+65 86056752
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 16:00:00 EET | Press release
ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer at ViTAA Medical said: “The SVS deserves credit for its foresight in embracing advances in AI, digital healt
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 15:39:00 EET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 15:30:00 EET | Press release
Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specification that lets any payment provider add Klarna to AI agent checkout. “Agentic
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 12:05:00 EET | Press release
SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing on a rolling basis through December 2026. It takes SatSure’s total capital raised to INR 427 crore (c. USD 46 millio
Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 11:16:00 EET | Press release
In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
